Incyte Corp (NAS:INCY)
$ 57 -0.05 (-0.09%) Market Cap: 12.82 Bil Enterprise Value: 9.01 Bil PE Ratio: 17.27 PB Ratio: 2.37 GF Score: 86/100

Incyte Corp Data Highlights on Adenosine Program from AACR 2021 Transcript

Apr 12, 2021 / 12:30PM GMT
Release Date Price: $79.87 (-0.11%)
Operator

Hello, and welcome to the Incyte data highlights on the adenosine program from AACR 2021. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Christine Chiou. Please go ahead.

Christine Chiou
Incyte Corporation - Head of IR

Thank you, Kevin. Good morning, and welcome to Incyte's adenosine program highlights from AACR conference call and webcast. The slides used today are available for download on the Investors section of incyte.com. I'm joined on the call today by Steven Stein, our Chief Medical Officer; and by Patrick Mayes, Incyte's Vice President of Biotherapeutics Research. Also joining for the Q&A session following our prepared remarks, Dash Dhanak, our Chief Scientific Officer.

Before we begin, I would like to remind you that safe harbor rules govern our remarks today and any forward-looking statements that we may make. I, therefore, encourage you to review the risk factors detailed in Incyte's SEC filings included in our Form 10-K for the year ended December 31, 2020.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot